Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
biotechs: Archive
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
LGNDNegative Net Change ANIPNegative Net Change ACADNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.
LGNDNegative Net Change AGENNegative Net Change VKTXNegative Net Change TVTXNegative Net Change
biotechs earnings medical
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
LGNDNegative Net Change ANIPNegative Net Change ITCINegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
LGNDNegative Net Change PCRXPositive Net Change ANIPNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
by Zacks Equity Research
Beam Therapeutics (BEAM) reports mixed first-quarter results. The company remains focused on pipeline development.
LGNDNegative Net Change BEAMNegative Net Change ENTXNegative Net Change THRDPositive Net Change
biotechs earnings
Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates
by Zacks Equity Research
Halozyme (HALO) reports mixed first-quarter 2024 earnings. The company maintains revenue guidance for 2024.
RHHBYPositive Net Change JNJPositive Net Change HALONegative Net Change LGNDNegative Net Change
biotechs earnings
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
by Zacks Equity Research
Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.
SNYNegative Net Change BIIBNegative Net Change LGNDNegative Net Change DNLINegative Net Change
biotechnology biotechs earnings pharmaceuticals
Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.
ANIPNegative Net Change ANABNegative Net Change ARGXNegative Net Change GHPositive Net Change
biotechs medical oncology-screening
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.
JAZZPositive Net Change LGNDNegative Net Change AXSMPositive Net Change CTKBPositive Net Change
biotechs earnings
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
UTHRNegative Net Change LGNDNegative Net Change ANIPNegative Net Change RCKTNegative Net Change
biotechs earnings gene-editing gene-therapy medical
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
LGNDNegative Net Change ANIPNegative Net Change APLSPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
by Zacks Equity Research
Vertex's (VRTX) first-quarter earnings and revenues surpass estimates. Higher sales of Trikafta/Kaftrio in U.S. and ex-U.S. markets drive the top line.
VRTXPositive Net Change LGNDNegative Net Change CRSPNegative Net Change ALPNNegative Net Change
biotechs
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
ANIPNegative Net Change ADVMNegative Net Change ARVNNegative Net Change ABSINegative Net Change
biotechnology biotechs pharmaceuticals
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.
VRTXPositive Net Change ANIPNegative Net Change CRSPNegative Net Change TSVTPositive Net Change
biotechs
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
CPRXNegative Net Change ADVMNegative Net Change ARGXNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.
CPRXNegative Net Change ANIPNegative Net Change ADVMNegative Net Change ARGXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
by Kinjel Shah
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
TEVANegative Net Change PRGONegative Net Change ACADNegative Net Change IOVANegative Net Change VTRSNegative Net Change
biotechs pharmaceuticals
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline.
ANIPNegative Net Change ANABNegative Net Change ARGXNegative Net Change IOVANegative Net Change
biotechs cell-therapy earnings medical
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.
CPRXNegative Net Change ANIPNegative Net Change ADVMNegative Net Change VTRSNegative Net Change
biotechs medical pharmaceuticals
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
BMRNNegative Net Change LGNDNegative Net Change BPMCNegative Net Change IMVTPositive Net Change KYMRNegative Net Change
biotechnology biotechs
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
by Zacks Equity Research
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
REGNNegative Net Change ALNYPositive Net Change NVSNegative Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
REGNNegative Net Change LGNDNegative Net Change ANIPNegative Net Change RAREPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
by Zacks Equity Research
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
AZNPositive Net Change NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change
biotechs
Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
by Zacks Equity Research
Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.
LGNDNegative Net Change PBYINegative Net Change ANIPNegative Net Change VYGRPositive Net Change
biotechs earnings
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
SNYNegative Net Change AMRNNegative Net Change ANIPNegative Net Change KYMRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals